NSE: COLPAL | BSE: 500830

Expensive Performer

Download real time

2423.30 -41.30 (-1.68%)

37.70% Fall from 52W High

783.3K NSE+BSE Volume

NSE 05 Sep, 2025 3:31 PM (IST)

65,910.3

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Colgate-Palmolive (India) Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for COLPAL, BSE:500830 Colgate-Palmolive (India) Ltd.

Colgate-Palmolive (India) Ltd.

28 Jan 2022

2423.30

-1.68%

Colgate Palmolive India

Hold: Colgate-Palmolive (India) ...

Recommendation Target

ICICI Securities Limited

Volume growth remains muted; margins peak out in India. The company has more than 50% market share in the toothpaste category. The major brands include Colgate Dental Cream, Colgate Total, Colgate Max-Fresh. With the changing consumer preference for naturals products, CPIL is focusing on growing Colgate Vedshakti brand. Recently, it has launched toothpaste for Diabetics,...

Number of FII/FPI investors decreased from 892 to 860 in Jun 2025 qtr

Colgate-Palmolive (India) Ltd.

28 Jan 2022

2423.30

-1.68%

Result Update:Colgate-Palmoliv

Buy: Colgate-Palmolive (India) ...

Target

Axis Direct

Maintain BUY with revised TP of Rs. 1,650 (earlier Rs. 1,765) at 39x FY24E EPS.

Number of FII/FPI investors decreased from 892 to 860 in Jun 2025 qtr

Colgate-Palmolive (India) Ltd.

27 Jan 2022

2423.30

-1.68%

COLGATE PALMOLIVE IN

Accumulate: Colgate-Palmolive (India) ...

Target

Prabhudas Lilladhar

back of 1) Increased Input cost inflation and 2) Low volume growth expected margins over FY21-24 post sharp 460bps gains in FY21. Premiumisation trend continues with Colgate Total, Sensitive and Charcoal...

Number of FII/FPI investors decreased from 892 to 860 in Jun 2025 qtr

Colgate-Palmolive (India) Ltd.

27 Jan 2022

2423.30

-1.68%

Weak result trend persists

Neutral: Colgate-Palmolive (India) ...

Target

Motilal Oswal

Colgate (CLGT) reported another weak quarter of results, with sales/EBITDA/PAT growth in the 24% range. In addition to weak sales growth, material cost pressures are evident; margins came in marginally below estimates despite the sharp 24% cut in ad spends YoY. We maintain a Neutral rating as we do not see any valuation re-rating unless the sales growth traction returns....

Colgate-Palmolive (India) Ltd. is trading above its 50 day SMA of 2326.2

Colgate-Palmolive (India) Ltd.

08 Dec 2021

2423.30

-1.68%

Colgate Palmolive Ltd

Buy: Colgate-Palmolive (India) ...

Joindre Capital Services

Colgate-Palmolive (India) Ltd. is trading above its 50 day SMA of 2326.2

Colgate-Palmolive (India) Ltd.

03 Nov 2021

2423.30

-1.68%

COLGATE PALMOLIVE INDIA LTD

Hold: Colgate-Palmolive (India) ...

Recommendation Target

Geojit BNP Paribas

Higher pricing, optimizing trade spending, enhancing productivity and premiumization are core themes, the company plans to focus on in the coming quarters. However, input cost inflation, higher Ad spends to revive sales and weak rural demand scenario remain headwinds in the near-term. Hence, we downgrade our rating on the stock to HOLD with a revised TP of Rs. 1,650 based on 37.5x FY23E adj. EPS. Topline sees further recovery, as penetration remains strong During Q2FY22, company's standalone revenue rose 16.1% QoQ to Rs. 1,344cr (+5.2%...

Colgate-Palmolive (I.. has an average target of 2632.38 from 8 brokers.

Colgate-Palmolive (India) Ltd.

26 Oct 2021

2423.30

-1.68%

Result Update:Colgate-Palmoliv

Buy: Colgate-Palmolive (India) ...

Target

Axis Direct

Maintain BUY with revised TP of Rs. 1,765 (earlier Rs. 1,875) as we also lower our multiple a notch to 39x FY24E EPS.

Colgate-Palmolive (I.. has an average target of 2632.38 from 8 brokers.

Colgate-Palmolive (India) Ltd.

25 Oct 2021

2423.30

-1.68%

Sales growth remains tepid; outlook weak

Neutral: Colgate-Palmolive (India) ...

Target

Motilal Oswal

CLGT's 2QFY22 result was in line with our estimates. Two-year average sales growth, at 5.2% in 2QFY22, continues to remain in the 4-6% range seen in recent quarters, with little indication of an improvement, despite consistent advertising spends. With: a) the launch of the Non-Oral Care portfolio, and b) investments under the brush twice a day' campaign seemingly on the back burner, it is unlikely to return to double-digit sales growth seen over FY0815 anytime soon. We maintain our Neutral view on weak topline growth, rising material cost pressures, and limited scope for price hikes....

Colgate-Palmolive (I.. has an average target of 2632.38 from 8 brokers.

Colgate-Palmolive (India) Ltd.

25 Oct 2021

2423.30

-1.68%

Q2FY22 Result Update - Growth unexciting, valuations offer comfort - ACCUMULATE

Accumulate: Colgate-Palmolive (India) ...

Target

Prabhudas Lilladhar

We are cutting EPS estimates by 6.4%/3.1%/3.5% for FY22/FY23/FY24 on the back of 1) Increased Input cost inflation and 2) Low volume growth expected in 2H22 given large base in 4Q21 and 3) Flattish EBIDTA margins over FY2124 post sharp 460bps gains in FY21. Increased promotions during the Quarter resulted in ~4.2% volume growth but with pressure on realisations. CLGT is...

Colgate-Palmolive (India) Ltd. is trading above its 50 day SMA of 2326.2

Colgate-Palmolive (India) Ltd.

30 Jul 2021

2423.30

-1.68%

Colgate Palmolive India

Buy: Colgate-Palmolive (India) ...

Target

ICICI Securities Limited

Favourable RM costs; elevated margins to sustain The company has more than 50% market share in the toothpaste category. The major brands include Colgate Dental Cream, Colgate Total, Colgate Max-Fresh. With the changing consumer preference for naturals products, the company is focusing on growing Colgate Vedshakti. Recently, it launched toothpaste for diabetics, Colgate Vedshakti Oil Pulling & Vedshakti mouth spray. Colgate has a distribution reach of 6.5 million outlets. The company commands one of the highest gross margins in the industry and spends...

Colgate-Palmolive (I.. has an average target of 2632.38 from 8 brokers.

Is Colgate-Palmolive (India) Ltd. worth buying?

407 Votes:

Buy 76.66%

Sell 13.51%

Hold 9.83%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf